

Task 2: Molecular Docking of EGFR Family Kinase Domains

Objective

In this task, you will perform **blind molecular docking** of small molecules against the **kinase domains of the EGFR family** to compare binding affinities and interaction patterns.

You will integrate:

- Structural biology
 - Protein structure modeling
 - Molecular docking
 - Comparative drug–target analysis
-

Biological Background (for Students)


The **EGFR (Epidermal Growth Factor Receptor) family** consists of four closely related receptor tyrosine kinases:

- EGFR / ErbB1
- ErbB2 (HER2)
- ErbB3 (HER3)
- ErbB4 (HER4)

These proteins play a central role in:

- Cell growth and proliferation
- Cancer development
- Targeted cancer therapy

Many anti-cancer drugs, such as **osimertinib**, specifically inhibit the **kinase domain** of EGFR family members.



Overview of the Task

You will:

1. Prepare **complete kinase-domain structures** for EGFR family proteins
2. Prepare **small-molecule ligands**
3. Perform **blind docking**
4. Compare docking results across proteins and ligands

Task 4.1: Download Protein Structures from PDB

Objective



Obtain experimentally resolved structures of EGFR family kinase domains.

What you must do

1. Search the **Protein Data Bank (PDB)** for kinase-domain structures of:
 - EGFR (ErbB1)
 - ErbB2
 - ErbB3
 - ErbB4
 2. Select structures that:
 - Contain the kinase domain
 - Have reasonable resolution
 3. Download the **PDB files**
-

Required output

- One PDB file per protein
 - A table listing:
 - Protein name
 - PDB ID
 - Resolution
 - Missing residues (yes/no)
-





Task 2.2: Complete Protein Structures Using AlphaFold

Objective

Generate **full-length, structurally complete kinase domains** by modeling missing residues.

What you must do

1. Identify **missing residues** in each PDB structure.
2. Use **AlphaFold** (or AlphaFold-derived models) to:
 - Predict the full kinase-domain structure
3. Merge:
 - Experimental PDB structure
 - AlphaFold-predicted regions
4. Clean the final structure:
 - Remove unresolved fragments
 - Ensure correct chain continuity

- Remove crystallization artifacts (water, ions, ligands)
-

Required output

- One **final, cleaned PDB file** per protein
 - Short description of:
 - Which residues were missing
 - How AlphaFold was used to complete them
-

Task 2.3: Ligand Preparation

Objective

Prepare bioactive compounds and a known anti-cancer drug for docking.

Ligands to use

Ligand	Type
Curcumin	Natural bioactive compound
Apigenin	Natural bioactive flavonoid
Osimertinib	FDA-approved anti-cancer drug


What you must do

1. Download ligand structures from a chemical database (e.g., PubChem)
 2. Convert ligands to docking-ready format
 3. Perform ligand preparation:
 - Add hydrogens
 - Optimize geometry
 - Assign charges
-

Required output

- One prepared ligand file per compound
- A table summarizing:
 - Ligand name

- Molecular weight
 - Number of rotatable bonds
-



Task 2.4: Blind Molecular Docking

Objective

Perform **blind docking** of each ligand against each EGFR family kinase domain.

What you must do

1. Define a **blind docking grid** that covers the entire kinase domain
2. Dock:
 - Curcumin
 - Apigenin
 - Osimertinibagainst:
 - EGFR
 - ErbB2

- ErbB3
- ErbB4
- 3. Use the **same docking parameters** for all runs

📌 This results in **12 docking experiments** total.

Required output

For each docking run:

- Docking score / binding energy
 - Best-scoring pose
 - Docking log file
-

Task 2.5: Results Comparison and Analysis

Objective

Compare binding behavior across ligands and proteins.

What you must analyze

1. Compare **binding affinities**:
 - Natural compounds vs osimertinib
 2. Compare **binding consistency** across EGFR family members
 3. Identify:
 - Strongest ligand–protein combinations
 - Selectivity patterns
-

Required tables and figures

- A **comparison table** of docking scores
 - Bar plots or heatmaps of binding energies
 - Visualization of top docking poses in the kinase domain
-

Task 2.6: Biological Interpretation

Required written discussion

You must answer:

- How do curcumin and apigenin compare to osimertinib?
 - Are natural compounds predicted to bind all EGFR family members equally?
 - What structural features may explain differences in binding?
 - What are the **limitations** of docking-based predictions?
-

Final Deliverables for Task 2

You must submit:

- ☒ Final cleaned protein PDB files
 - ☒ Prepared ligand files
 - ☒ Docking score tables
 - ☒ Docking pose visualizations
 - ☒ Comparative analysis and interpretation
-

Learning Outcomes

After completing this task, you should be able to:

- Prepare protein structures for docking
- Use AlphaFold to model missing regions
- Perform blind molecular docking
- Compare drug-like and natural compounds
- Interpret docking results in a cancer biology context